Therapeutic ultrasound developer Misonix has filed a Form 10-K with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended June 30, 2016. It has also provided the SEC with preliminary results for its second fiscal quarter (end-December 31).
The move comes after the company received a deficiency letter in November from the Nasdaq Stock Market due to delays in its quarterly and annual reports.
For its 2016 fiscal year, Misonix reported net sales of $23.1 million, up 4.1% over the prior year, and a net loss of $1.2 million, compared with net income of $5.6 million in 2015.
Preliminary net sales for the second fiscal quarter were $6 million, flat with the same period in 2015. For the six months ended December 31, preliminary sales were $12.2 million, an 8% increase over $11.3 million in the first six months of the prior year.
The company is working to complete its Form 10-Qs for the quarters ended September 30 and December 31, which it intends to file no later than March 13, it said.
